ATAI Life Sciences BV (NASDAQ:ATAI) — Stock Price
ATAI Life Sciences BV (NASDAQ:ATAI) is currently trading at $7.25 USD, up 0.00% today. Over the past 52 weeks, shares have ranged between $3.35 and $7.25. This page tracks ATAI Life Sciences BV's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see ATAI market cap.
ATAI Life Sciences BV (ATAI) Stock Price Chart — Daily History & Trading Volume
The chart below tracks ATAI Life Sciences BV's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
ATAI Life Sciences BV Income Statement — Revenue, Profit & Earnings by Year
ATAI Life Sciences BV's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $4.09 Million | $308.00K | $314.00K | $233.00K | $20.38 Million |
| Cost of Revenue | $1.01 Million | $473.00K | $319.00K | $168.00K | $47.00K |
| Gross Profit | $3.08 Million | $-165.00K | $-5.00K | $65.00K | $20.33 Million |
| Research & Development | $53.06 Million | $54.98 Million | $61.88 Million | $74.14 Million | $47.91 Million |
| SG&A | $65.09 Million | $45.32 Million | $61.18 Million | $69.65 Million | $92.75 Million |
| Total Operating Expenses | $102.84 Million | $102.53 Million | $125.47 Million | $144.50 Million | $140.65 Million |
| Operating Income | $-99.76 Million | $-102.69 Million | $-125.47 Million | $-144.43 Million | $-120.33 Million |
| EBITDA | $-98.75 Million | $-102.22 Million | $-125.15 Million | $-144.26 Million | $-120.28 Million |
| EBIT | $-99.76 Million | $-102.69 Million | $-125.47 Million | $-144.43 Million | $-120.33 Million |
| Interest Expense | $1.16 Million | $3.12 Million | $2.66 Million | $923.00K | $66.91 Million |
| Income Before Tax | $-659.85 Million | $-150.93 Million | $-42.88 Million | $-151.19 Million | $-178.23 Million |
| Income Tax Expense | $298.00K | $-881.00K | $1.02 Million | $6.23 Million | $-3.99 Million |
| Net Income | $-660.05 Million | $-149.27 Million | $-40.22 Million | $-152.38 Million | $-167.81 Million |
ATAI Life Sciences BV Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes ATAI Life Sciences BV's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $310.54 Million | $159.39 Million | $293.48 Million | $305.44 Million | $414.17 Million |
| Total Current Assets | $275.68 Million | $80.12 Million | $185.59 Million | $287.14 Million | $375.08 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | $170.74 Million | $44.83 Million | $134.22 Million | $82.50 Million | $0.00 |
| Net Receivables | $14.43 Million | $1.35 Million | $2.26 Million | $5.63 Million | $6.32 Million |
| Inventory | — | — | $-25.00 Million | $-5.63 Million | — |
| Property, Plant & Equipment | — | — | — | $928.00K | $149.00K |
| Goodwill | $331.00K | $331.00K | $0.00 | — | — |
| Total Liabilities | $88.54 Million | $42.83 Million | $49.16 Million | $39.67 Million | $28.21 Million |
| Total Current Liabilities | $23.48 Million | $24.95 Million | $20.12 Million | $19.90 Million | $20.93 Million |
| Long-term Debt | — | $14.13 Million | $17.88 Million | $14.70 Million | $743.00K |
| Net Debt | $-83.23 Million | $7.20 Million | $-25.89 Million | $-175.27 Million | $-361.52 Million |
| Total Stockholder Equity | $221.87 Million | $116.30 Million | $242.96 Million | $260.74 Million | $376.91 Million |
| Retained Earnings | $-1.36 Billion | $-700.21 Million | $-550.94 Million | $-510.19 Million | $-357.80 Million |
ATAI Life Sciences BV Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how ATAI Life Sciences BV generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-102.67 Million | $-82.44 Million | $-84.12 Million | $-104.47 Million | $-63.25 Million |
| Capital Expenditures | $901.00K | $95.00K | $590.00K | $1.02 Million | $1.13 Million |
| Free Cash Flow | $-103.58 Million | $-82.53 Million | $-84.71 Million | $-105.49 Million | $-64.37 Million |
| Investing Cash Flow | $-109.13 Million | $59.17 Million | $-53.30 Million | $-86.85 Million | $-81.28 Million |
| Financing Cash Flow | $269.48 Million | $5.37 Million | $-8.36 Million | $20.79 Million | $409.86 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | $14.21 Million | $25.49 Million | $32.98 Million | $42.38 Million | $63.36 Million |
| Depreciation | $1.01 Million | $473.00K | $319.00K | $168.00K | $47.00K |
| Change in Cash | $57.80 Million | $-17.53 Million | $-145.58 Million | $-171.65 Million | $265.02 Million |
ATAI Life Sciences BV Earnings History — EPS Actual vs. Analyst Estimates
Track ATAI Life Sciences BV's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 20, 2026 | -0.08 | -0.10 | +17.77% |
| Mar 26, 2026 | -1.73 | -0.10 | -1552.34% |
| Nov 12, 2025 | -0.28 | -0.11 | -154.55% |
| Aug 14, 2025 | -0.14 | -0.12 | -16.67% |
| May 13, 2025 | -0.15 | -0.18 | +16.67% |
| Mar 26, 2025 | -0.24 | -0.15 | -60.00% |
| Nov 05, 2024 | -0.16 | -0.16 | +0.00% |
| Aug 06, 2024 | -0.36 | -0.16 | -125.00% |